Marshall Wace LLP Has $7.27 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Marshall Wace LLP raised its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 641.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 175,913 shares of the company's stock after buying an additional 152,191 shares during the quarter. Marshall Wace LLP owned about 0.37% of Mirum Pharmaceuticals worth $7,274,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of MIRM. Geode Capital Management LLC increased its stake in Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after purchasing an additional 29,017 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its position in shares of Mirum Pharmaceuticals by 25.5% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock valued at $6,021,000 after buying an additional 29,545 shares in the last quarter. AlphaQuest LLC raised its stake in Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after buying an additional 1,658 shares during the period. Golden State Equity Partners lifted its holdings in Mirum Pharmaceuticals by 1,390.8% during the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company's stock worth $801,000 after acquiring an additional 18,080 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $277,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on MIRM shares. Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. HC Wainwright boosted their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $58.20.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock traded up $0.33 during trading on Friday, hitting $40.80. 186,097 shares of the stock were exchanged, compared to its average volume of 521,493. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The company has a fifty day moving average price of $44.12 and a 200-day moving average price of $43.97. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -20.20 and a beta of 1.00. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.83 and a 1-year high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. As a group, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 1,064 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $51,306.08. Following the completion of the sale, the senior vice president now owns 4,232 shares of the company's stock, valued at $204,067.04. The trade was a 20.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $438,898.44. Following the completion of the sale, the chief executive officer now owns 115,920 shares of the company's stock, valued at approximately $5,589,662.40. The trade was a 7.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,557 shares of company stock worth $4,726,040. Insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.